Clinical trial

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

NCT05532696

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-09-27

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2022-09-27Date precision: day

Registry last updated2024-06-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorunresolved

Non Small Cell Lung Cancerunresolved

HER2 Mutationsunresolved

Interventions

ABT-101DRUG

Sponsors & collaborators

Anbogen Therapeutics, Inc.lead sponsor

Mapped research locations

TaipeiTaiwan2 TaichungTaiwan1 TainanTaiwan1 TaoyuanTaiwan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05532696 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.